Gynesonics, a USA, Redwood City-based healthcare company specializing in minimally invasive treatments for symptomatic uterine fibroids, has secured $42.5 million in funding, bringing the total amount raised to $67.2 million since their initial investment in April 2023. The round was led by prominent investors such as Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital, with participation from new investors including MVM Partners and other healthcare-focused entities. Gynesonics intends to utilize the funds to expand its operations and broaden its market presence.
Led by CEO Skip Baldino, Gynesonics is dedicated to developing and delivering innovative, incision-free, and uterus-preserving transcervical technologies designed for diagnostic and therapeutic applications. The company's flagship product, the Sonata System®, is an FDA-cleared medical device that enables both diagnostic intrauterine imaging and transcervical treatment for symptomatic uterine fibroids, a condition that affects approximately 80% of adult women. Prior to the advent of the Sonata System, the removal of fibroids often required invasive procedures, such as hysterectomies, which entail higher risks and considerably longer recovery periods. With the Sonata System, fibroid removal can be completed in an outpatient procedure lasting about 45 minutes, allowing most patients to resume regular activities the following day. The system has received CE marking and is approved for sale in various markets, including the European Union, the United Kingdom, Switzerland, and the United States.